Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2011

Open Access 01-12-2011 | Short report

Vascular endothelial growth factor-A and chemokine ligand (CCL2) genes are upregulated in peripheral blood mononuclear cells in Indian amyotrophic lateral sclerosis patients

Authors: Pawan K Gupta, Sudesh Prabhakar, Chandrika Abburi, Neel K Sharma, Akshay Anand

Published in: Journal of Neuroinflammation | Issue 1/2011

Login to get access

Abstract

Background

We have earlier shown that protein levels of vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) were elevated in Indian amyotrophic lateral sclerosis (ALS) patients. Here, we report the mRNA levels of VEGF-A and CCL2 in Indian ALS patients since they display extended survival after disease onset.

Methods

VEGF-A and CCL2 mRNA levels were measured in peripheral blood mononuclear cells (PBMCs) of 50 sporadic Indian ALS patients using Real Time Polymerase Chain Reaction (PCR) and compared with normal controls (n = 50). Their levels were adjusted for possible confounders like cigarette smoking, alcohol and meat consumption.

Results

VEGF-A and CCL2 mRNA levels were found to be significantly elevated in PBMCs in ALS patients as compared to controls. PBMCs from definite ALS revealed higher VEGF-A mRNA expression as compared to probable and possible ALS. CCL2 mRNA levels were found to be unaltered when definite, probable and possible ALS were compared. PBMCs from patients with respiratory dysfunction showed much higher VEGF-A and CCL2 elevation when compared to patients without respiratory dysfunction. No association of smoking, alcohol and meat consumption with VEGF-A and CCL2 was observed after analyzing the data with univariate and multivariate analysis.

Conclusion

VEGF-A and CCL2 mRNA upregulation in PBMCs may have a clinico-pathological/etiological/epidemiological association with ALS pathogenesis. The cross-cultural and cross-ethnic investigations of these molecules could determine if they have any role in enhancing the mean survival time unique to Indian ALS patients.
Appendix
Available only for authorised users
Literature
1.
Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000, 6: 389-395. 10.1038/74651.CrossRefPubMed
2.
Storkebaum E, Lambrechts D, Carmeliet P: VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays. 2004, 26: 943-954. 10.1002/bies.20092.CrossRefPubMed
3.
Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W, Herbert JM, Collen D, Carmeliet P: Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001, 28: 131-138. 10.1038/88842.CrossRefPubMed
4.
Hwang DH, Lee HJ, Park IH, Seok JI, Kim BG, Joo IS, Kim SU: Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther. 2009, 10: 1234-1244.CrossRef
5.
Madrigal JL, Leza JC, Polak P, Kalinin S, Feinstein DL: Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J Neurosci. 2009, 29: 263-267. 10.1523/JNEUROSCI.4926-08.2009.CrossRefPubMed
6.
Nalini A, Thennarasu K, Gourie-Devi M, Shenoy S, Kulshreshtha D: Clinical characteristics and survival pattern of 1,153 patients with amyotrophic lateral sclerosis: experience over 30 years from India. J Neurol Sci. 2008, 272: 60-70. 10.1016/j.jns.2008.04.034.CrossRefPubMed
7.
Bradley WG: Commentary on Professor Stephen Hawking's disability advice. Annals of Neurosciences. 2009, 16: 101-102. 10.5214/ans.0972.7531.2009.160303.CrossRef
8.
Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ: Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology. 2002, 59: 280-282.CrossRefPubMed
9.
Gupta PK, Prabhakar S, Sharma S, Anand A: Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in Amyotrophic Lateral Sclerosis (ALS) patients. Journal of Neuroinflammation. 2011, 8: 47-10.1186/1742-2094-8-47.PubMedCentralCrossRefPubMed
10.
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A: The ALSFRS-R: a revised ALS functional rating scale that incorporates assessmentsof respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999, 169: 13-21. 10.1016/S0022-510X(99)00210-5.CrossRefPubMed
11.
Prabhakar S, Vinish M, Das CP, Anand A: Occurrence of PARK2 Mutations in a Never-Smoker Population with Parkinson's Disease in North India. Neuroepidemiology. 2010, 35: 152-159. 10.1159/000313855.CrossRefPubMed
12.
Meister B, Grünebach F, Bautz F, Brugger W, Fink FM, Kanz L, Möhle R: Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma. Eur J Cancer. 1999, 35: 445-449. 10.1016/S0959-8049(98)00387-6.CrossRefPubMed
13.
Ebihara N, Yamagami S, Yokoo S, Amano S, Murakami A: Involvement of C-C chemokine ligand 2-CCR2 interaction in monocyte-lineage cell recruitment of normal human corneal stroma. J Immunol. 2007, 178: 3288-3292.CrossRefPubMed
14.
Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR, Appel SH: Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol. 2004, 55: 221-235. 10.1002/ana.10805.CrossRefPubMed
15.
Lu L, Zheng L, Viera L, Suswam E, Li Y, Li X, Estévez AG, King PH: Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression. J Neurosci. 2007, 30: 7929-38.CrossRef
16.
Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A, Bornes S, Musson R, Hansen V, Beckman L, Adolfsson R, Pall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Dewerchin M, Shaw C, Moons L, Vlietinck R, Morrison KE, Robberecht W, Van Broeckhoven C, Collen D, Andersen PM, Carmeliet P: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003, 34: 383-394. 10.1038/ng1211.CrossRefPubMed
17.
Devos D, Moreau C, Lassalle P, Perez T, De Seze J, Brunaud-Danel V, Destée A, Tonnel AB, Just N: Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology. 2004, 62: 2127-2129.CrossRefPubMed
18.
Nygren I, Larsson A, Johansson A, Askmark H: VEGF-A is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis. Neuroreport. 2002, 13: 2199-2201. 10.1097/00001756-200212030-00007.CrossRefPubMed
19.
Iłzecka J: Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2004, 106: 289-93. 10.1016/j.clineuro.2003.12.007.CrossRefPubMed
20.
Cronin S, Greenway MJ, Ennis S, Kieran D, Green A, Prehn JH, Hardiman O: Elevated serum angiogenin levels in ALS. Neurology. 2006, 67: 1833-1836. 10.1212/01.wnl.0000244466.46020.47.CrossRefPubMed
21.
Nagata T, Nagano I, Shiote M, Narai H, Murakami T, Hayashi T, Shoji M, Abe K: Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol Res. 2007, 29: 772-776. 10.1179/016164107X229795.CrossRefPubMed
22.
Manzano R, Toivonen JM, Oliván S, Calvo AC, Moreno-Igoa M, Muñoz MJ, Zaragoza P, García-Redondo A, Osta R: Altered Expression of Myogenic Regulatory Factors in the Mouse Model of Amyotrophic Lateral Sclerosis. Neurodegener Dis. 2011, 8: 386-396. 10.1159/000324159.CrossRefPubMed
23.
Bogaert E, Van Damme P, Poesen K, Dhondt J, Hersmus N, Kiraly D, Scheveneels W, Robberecht W, Van Den Bosch L: VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiol Aging. 2010, 31: 2185-2191. 10.1016/j.neurobiolaging.2008.12.007.CrossRefPubMed
24.
Meng H, Zhang Z, Zhang R, Liu X, Wang L, Robin AM, Chopp M: Biphasic effects of exogenous VEGF on VEGF expression of adult neural progenitors. Neurosci Lett. 2006, 393: 97-101. 10.1016/j.neulet.2005.09.044.CrossRefPubMed
25.
Liu XS, Zhang ZG, Zhang RL, Gregg SR, Wang L, Yier T, Chopp M: Chemokine ligand 2 (CCL2) induces migration and differentiation of subventricular zone cells after stroke. J Neurosci Res. 2007, 85: 2120-2125. 10.1002/jnr.21359.CrossRefPubMed
26.
Zhao W, Xie W, Le W, Beers DR, He Y, Henkel JS, Simpson EP, Yen AA, Xiao Q, Appel SH: Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. J Neuropathol Exp Neurol. 2004, 63: 964-977.CrossRefPubMed
27.
Bartholdi D, Rubin BP, Schwab ME: VEGF mRNA induction correlates with changes in the vascular architecture upon spinal cord damage in the rat. Eur J Neurosci. 1997, 9: 2549-2560. 10.1111/j.1460-9568.1997.tb01684.x.CrossRefPubMed
28.
Rosenstein JM, Krum JM: New roles for VEGF in nervous tissue--beyond blood vessels. Exp Neurol. 2004, 187: 246-253. 10.1016/j.expneurol.2004.01.022.CrossRefPubMed
29.
Zheng C, Sköld MK, Li J, Nennesmo I, Fadeel B, Henter JI: VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochem Biophys Res Commun. 2007, 363: 989-993. 10.1016/j.bbrc.2007.09.088.CrossRefPubMed
30.
Cui LY, Liu MS, Tang XF: Single fiber electromyography in 78 patients with amyotrophic lateral sclerosis. Chin Med J (Engl). 2004, 117: 1830-1833.
Metadata
Title
Vascular endothelial growth factor-A and chemokine ligand (CCL2) genes are upregulated in peripheral blood mononuclear cells in Indian amyotrophic lateral sclerosis patients
Authors
Pawan K Gupta
Sudesh Prabhakar
Chandrika Abburi
Neel K Sharma
Akshay Anand
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2011
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-8-114

Other articles of this Issue 1/2011

Journal of Neuroinflammation 1/2011 Go to the issue

Research

Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis

Erratum

Erratum to: SDF1 in the dorsal corticospinal tract promotes CXCR4+ cell migration after spinal cord injury

Research

Differential aquaporin 4 expression during edema build-up and resolution phases of brain inflammation

Research

SDF1 in the dorsal corticospinal tract promotes CXCR4+ cell migration after spinal cord injury

Research

CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease

Short report

Interleukin-1α expression precedes IL-1β after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues